Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company vs GoodRx
Christopher G Youn;
Joo Yeon Kim;
Vivian B Yang;
Gordon H. Bae
ABSTRACT
In the United States, the financial burden of prescription medications has increased exponentially over time. Recently, Mark Cuban founded the Mark Cuban Cost Plus Drug Company (MCCPDC) to help address prescription medication unaffordability. To assess the efficacy of this new pharmaceutical model within dermatology, we conducted an observational cost study of common dermatologic drugs between MCCPDC and GoodRx in the New York, Los Angeles, and Chicago metropolitan areas. The average cost of 15 common dermatology medications was $17.00 through MCCPDC compared to $31.21 through GoodRx (P<0.001). The cost on GoodRx when isolating for the cheapest price available was $21.24 (P=0.026). Our results indicate that MCCPDC has the potential to improve the financial burden of prescription medications within dermatology and should be further explored.
Citation
Please cite as:
Youn CG, Kim JY, Yang VB, Bae GH
Improving Affordability in Dermatology: Cost Savings in Mark Cuban Cost Plus Drug Company Versus GoodRx